The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2015Comparison of Nedd4 and GBA for Improving Protein Handling and Reducing Alpha-synucleinopathy
Study Rationale:
Lysosomes are key intra-cellular organelles involved in the degradation of proteins including alpha-synuclein. Lysosomal protein degradation systems fail in... -
Target Validation, 2015Pathogenetic Mechanisms in Early-onset Parkinsonism Resulting from a Mutation in the Synaptojanin 1 Protein
Study Rationale:
Several proteins encoded by Parkinson’s disease (PD) genes have been linked to vesicular traffic (movement of molecules) at synapses (junctions between neurons)... -
Therapeutic Pipeline Program, 2016KH176 as a Novel Disease-modifying Therapeutic for Parkinson’s Disease
Study Rationale:
Mitochondrial dysfunction has a prominent role in the process of Parkinson’s disease (PD). Mutations in at least seven genes are known to underlie PD, most of them encode proteins that... -
Target Validation, 2015Validation of the Rip Kinase Pathway as a Therapeutic Target in Parkinson's Disease
Study Rationale:
A genetic connection has been shown over the past few years between Parkinson’s and Gaucher’s diseases, such that people with genetic mutations that cause Gaucher’s disease have a... -
Therapeutic Pipeline Program, 2016Long-term Cell Restorative Treatment for Parkinson’s Disease
Study Rationale:
Cell replacement therapies for Parkinson’s disease (PD) propose to replace the lost dopaminergic neurons in the brain. Transplanted fetal dopamine neurons have... -
Improved Biomarkers and Clinical Outcome Measures, 2015Validation of a Performance-based Assessment of Functional Ability Related to Cognition in Parkinson’s Disease
Study Rationale:
There is a pressing need for new treatments to address cognitive impairment in Parkinson’s disease, yet there is no consensus on how to best evaluate their...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.